NAS:RMTI (USA) Also trade in: Germany

Rockwell Medical Inc

$ 3.02 0.12 (4.14%)
Volume: 721,491 Avg Vol (1m): 420,704
Market Cap $: 195.39 Mil Enterprise Value $: 167.57 Mil
P/E (TTM): 0.00 P/B: 8.57
Earnings Power Value -2.93
Net Current Asset Value 0.2
Tangible Book 0.34
Projected FCF -2.86
Median P/S Value 4.61
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 7.1/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt range over the past 10 years
Min: 0.01, Med: 672.22, Max: 10000
Current: 10000
0.01
10000
Equity-to-Asset 0.41
Equity-to-Asset range over the past 10 years
Min: -0.59, Med: 0.63, Max: 0.92
Current: 0.41
-0.59
0.92
Interest Coverage No Debt
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -4.48
DISTRESS
GREY
SAFE
Beneish M-Score -2.07
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 14.61%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -53.91
Operating Margin range over the past 10 years
Min: -108.87, Med: -41.11, Max: -4.82
Current: -53.91
-108.87
-4.82
Net Margin % -55.09
Net Margin range over the past 10 years
Min: -108.39, Med: -41.58, Max: -4.51
Current: -55.09
-108.39
-4.51
ROE % -168.90
ROE range over the past 10 years
Min: -1304.41, Med: -60.37, Max: -8.96
Current: -168.9
-1304.41
-8.96
ROA % -75.73
ROA range over the past 10 years
Min: -220.66, Med: -34.14, Max: -7.47
Current: -75.73
-220.66
-7.47
ROC (Joel Greenblatt) % -747.26
ROC (Joel Greenblatt) range over the past 10 years
Min: -2678.13, Med: -433.63, Max: -52.63
Current: -747.26
-2678.13
-52.63
3-Year Total Revenue Growth Rate 4.60
3-Year Revenue Growth Rate range over the past 10 years
Min: -23.2, Med: 2.7, Max: 32
Current: 2.8
-23.2
32
3-Year Total EBITDA Growth Rate -29.10
N/A
3-Year EPS w/o NRI Growth Rate -28.10
N/A

» RMTI's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:RMTI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers    NAICS : 325412    SIC : 2834
Compare KAR:SEARL XKRX:067290 KAR:GLAXO BOM:524348 ISX:DVLA XPAR:AB SHSE:600385 ROCO:4120 SHSE:600671 XKRX:206640 TSE:7775 BOM:524669 UKEX:FARM JSE:ASC BOM:506197 XKRX:016580 BOM:500672 SZSE:300254 ASX:MVP XKRX:067080
Traded in other countries RWM.Germany
Address 30142 Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The company's drug products are Triferic and Calcitriol. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. It replaces the ongoing iron loss that occurs to patients during every hemodialysis treatment, via dialysate. Calcitriol is a generic drug for treating secondary hyperparathyroidism in dialysis patients. The company operates in one segment of hemodialysis market which involves the manufacture, sale, and distribution of hemodialysis products.

Ratios

Current vs industry vs history
PB Ratio 8.57
PB Ratio range over the past 10 years
Min: 1.73, Med: 7.87, Max: 950
Current: 8.57
1.73
950
PS Ratio 2.54
PS Ratio range over the past 10 years
Min: 0.47, Med: 3.9, Max: 15.05
Current: 2.54
0.47
15.05
EV-to-EBIT -4.80
EV-to-EBIT range over the past 10 years
Min: -80.4, Med: -12.2, Max: -1.2
Current: -4.8
-80.4
-1.2
EV-to-EBITDA -5.00
EV-to-EBITDA range over the past 10 years
Min: -1117.1, Med: -12.7, Max: -1.2
Current: -5
-1117.1
-1.2
EV-to-Revenue 2.60
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 3.6, Max: 15
Current: 2.6
0.4
15
Current Ratio 2.55
Current Ratio range over the past 10 years
Min: 0.49, Med: 2.45, Max: 12.58
Current: 2.55
0.49
12.58
Quick Ratio 2.30
Quick Ratio range over the past 10 years
Min: 0.35, Med: 1.98, Max: 11.68
Current: 2.3
0.35
11.68
Days Inventory 29.44
Days Inventory range over the past 10 years
Min: 21.75, Med: 25.61, Max: 78.49
Current: 29.44
21.75
78.49
Days Sales Outstanding 38.27
Days Sales Outstanding range over the past 10 years
Min: 23.3, Med: 32.18, Max: 43.79
Current: 38.27
23.3
43.79
Days Payable 25.85
Days Payable range over the past 10 years
Min: 25.23, Med: 36.88, Max: 125.48
Current: 25.85
25.23
125.48

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.80
3-Year Share Buyback Rate range over the past 10 years
Min: -39, Med: -13.1, Max: 9.6
Current: -0.8
-39
9.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 8.88
Price-to-Tangible-Book range over the past 10 years
Min: 2.68, Med: 8.34, Max: 98.28
Current: 8.88
2.68
98.28
Price-to-Median-PS-Value 0.66
Price-to-Median-PS-Value range over the past 10 years
Min: 0.12, Med: 0.66, Max: 3.57
Current: 0.66
0.12
3.57
Earnings Yield (Joel Greenblatt) % -20.73
Earnings Yield (Greenblatt) range over the past 10 years
Min: -86.6, Med: -8.2, Max: -1.2
Current: -20.73
-86.6
-1.2

More Statistics

Revenue (TTM) (Mil) $ 64
EPS (TTM) $ -0.66
Beta 1.43
Volatility % 94.11
52-Week Range $ 2.19 - 6.88
Shares Outstanding (Mil) 64.7

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y